Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 23;4(1):vdac076. doi: 10.1093/noajnl/vdac076

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Response to further chemotherapy or radiotherapy differs between isogenic hypermutant and non-hypermutant GBM. (A) Immunoblot analysis of MGMT in isogenic hypermutant and non-hypermutant recurrent GBM and (B) assessment of MGMT methylation status using methylation-specific polymerase chain reaction analysis showing maintenance of MGMT methylation despite upregulation in 1123R9. Assessment of clonogenic survival in (C) hypermutant and (D) non-hypermutant tumors against combinations of TMZ and/or 06BG (N = 3). (E) Assessment of in vitro clonogenic survival against a single dose of 2Gy in hypermutant and non-hypermutant tumors. (F) in vivo assessment of tumor response to a fractionated radiotherapy regime (20Gy/10 fractions) in hypermutant and non-hypermutant GBM.